Dallas, Texas – November 28, 2023 – LexaGene Life Sciences, an innovative, molecular diagnostics company that is commercializing its MiQLab System for automated, microbial contamination testing, is providing the following update on the Company’s efforts in development of the 2nd generation MiQLab System for adoption for routine testing during the manufacturing of biologics. The Company…
VIEW RELEASEDallas, Texas – November 15, 2023 – Fletcher Spaght & Associates (“FSA”) a leading biopharma consulting firmed firm based in Boston, MA, has been retained by LexaGene Life Sciences, LLC (“LexaGene”) since early 2023 to provide ongoing consulting support and services to LexaGene. Throughout this ongoing engagement FSA has been in detailed discussions with the…
VIEW RELEASEDallas, Texas – October 31, 2023 — A critical component to enhancing the LexaGene Life Sciences (“LexaGene”) MiQLab® System is a renewal of the license for the use of certain technologies developed by LexaGene Life Science’s Chief Technology Officer Dr. Jack Regan and others at the Lawrence Livermore National Laboratory (“LLNL”). These patented technologies are…
VIEW RELEASEDallas, Texas – September 30, 2023 — LEXAGENE LIFE SCIENCES — A NEW ERA OF LEADERSHIP AND INNOVATION IN BIOPHARMACEUTICAL CONTAMINATION TESTING “Our solution will help secure the safe and fast availability of medications needed by humans, our pets and food production animals.” LexaGene Life Sciences, LLC (“LLS”) was formed in 2023 to acquire and…
VIEW RELEASE